COMMUNIQUÉS West-GlobeNewswire

National MS Society Launches Campaign to End MS, Declaring for the First Time: Ending MS Is Within Reach
01/10/2026
Five-year, $1 billion campaign to lead the way in ending MS, anchored by the Society's first-ever national research symposium and a landmark day of action in New York City NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- The [...]
Communiqué de presse : Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée
01/10/2026
Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée REGN20423, un anticorps monoclonal anti-IL-13 à action prolongée en phase clinique [...]
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
01/10/2026
Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is [...]
Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine
01/10/2026
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1 -mutated populations, respectively, versus standard endocrine therapy plus everolimus 1 By targeting [...]
IBA et Telix renforcent leur collaboration avec un accord de distribution de la technologie QIS® d’ARTMS
01/10/2026
IBA proposera le système d’irradiation QUANTM ® aux utilisateurs de cyclotrons partout dans le monde, afin d’accélérer la production locale de radio-métaux destinés à la théranostique. Louvain-la-Neuve, Belgique, 01 [...]
IBA and Telix strengthen ties through agreement to distribute ARTMS’s QIS®
01/10/2026
IBA to offer QUANTM ® Irradiation System solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics Louvain-la-Neuve, Belgium – October 1st, 2026, 7 a.m. – IBA (Ion [...]
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
01/10/2026
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical [...]
Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions
01/10/2026
New real-world results for Vabysmo in nAMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals 1-3 Advanced AI-enabled analysis of imaging [...]
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
01/10/2026
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients [...]
Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD
01/10/2026
Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD Phase 1 study is evaluating the safety, tolerability and [...]
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
01/10/2026
Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG ( [...]
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
30/09/2026
NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a clinical stage biotechnology company focused on developing highly selective [...]
Oculis Announces Resignation of Lionel Carnot from Board of Directors
30/09/2026
Oculis Announces Resignation of Lionel Carnot from Board of Directors ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company [...]
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
30/09/2026
GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option [...]
COBRA Alternatives After Job Loss: How Healthcare Sharing Membership Works
30/09/2026
Healthcare sharing memberships enroll year-round, without an open enrollment window or COBRA-style election deadline. After a job loss, individuals and households typically weigh four options: the full COBRA premium, an [...]
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026
30/09/2026
Company announcement – No. 51 / 2026 Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 Copenhagen, Denmark, September 30, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") ( [...]
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
30/09/2026
Conference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026 BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel [...]
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
30/09/2026
Clinical trial designed to demonstrate proof-of-concept for soquelitinib in the treatment of hidradenitis suppurativa and evaluate its effects on Th17 biology SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE [...]
Scienture Holdings, Inc. Announces Reverse Stock Split
30/09/2026
COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to [...]

Pages